TrialThe Journal of clinical endocrinology and metabolism2023

Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity.

Raymond S Douglas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.